Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

The diabetes startup is prescribing GLP-1 drugs for weight loss to help employers manage costs. Its CEO says it's nearing ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

Debate over the risks and benefits of the population weight loss drugs like Ozempic, Wegovy, and Zepbound finally came to an ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

Will Medicare end Novo Nordisk's obesity drug boom? It's not surprising that CMS chose Ozempic, Wegovy, and Rybelsus for Medicare drug price negotiations. Between November 2023 and October 2024 ...

The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may ...